ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy

  • Authors:
    • Hirotaka Kamikozuru
    • Hidekazu Kuramochi
    • Kazuhiko Hayashi
    • Go Nakajima
    • Masakazu Yamamoto
  • View Affiliations

  • Published online on: May 1, 2008     https://doi.org/10.3892/ijo.32.5.1091
  • Pages: 1091-1096
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Excision repair cross-complementation 1 (ERCC1) has been reported to play a major role in the response to platinum-based therapies. It has recently been proposed that a synonymous polymorphism at codon 118 converting a common codon usage (AAC) to an infrequent one (AAT) may impair ERCC1 translation and to affect the response to cisplatin chemotherapy. We analyzed the association between this polymorphism and clinical outcome in 67 pancreatic cancer patients treated with cisplatin and S-1 or with S-1 alone. ERCC1 codon 118 polymorphism was analyzed using PCR-RFLP. Thirty-nine of the patients (58.2%) were homozygous for AAC codon, 7 (10.4%) were homozygous for AAT codon, and 21 (31.3%) were heterozygous. Among those treated with cisplatin and S-1, no significant difference in objective response rate was observed between genotypes. However, the patients with one or two AAT codons had a significantly longer progression-free survival (PFS) and overall survival (OS) than those homozygous for AAC allele (PFS: 338 days vs 106 days, p=0.006, OS: 763 days vs 415 days, p=0.030). In contrast, no significant difference in PFS or OS was observed between genotypes among the patients treated with S-1 alone. ERCC1 polymorphism may be a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.

Related Articles

Journal Cover

May 2008
Volume 32 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kamikozuru, H., Kuramochi, H., Hayashi, K., Nakajima, G., & Yamamoto, M. (2008). ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. International Journal of Oncology, 32, 1091-1096. https://doi.org/10.3892/ijo.32.5.1091
MLA
Kamikozuru, H., Kuramochi, H., Hayashi, K., Nakajima, G., Yamamoto, M."ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy". International Journal of Oncology 32.5 (2008): 1091-1096.
Chicago
Kamikozuru, H., Kuramochi, H., Hayashi, K., Nakajima, G., Yamamoto, M."ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy". International Journal of Oncology 32, no. 5 (2008): 1091-1096. https://doi.org/10.3892/ijo.32.5.1091